

05-86000-22

Original Effective Date: 02/15/04

Reviewed: 12/08/23

Revised: 07/01/24

## Subject: Tumor/Genetic Markers

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

<a href="#">Position Statement</a>	<a href="#">Billing/Coding</a>	<a href="#">Reimbursement</a>	<a href="#">Program Exceptions</a>	<a href="#">Definitions</a>	<a href="#">Related Guidelines</a>
<a href="#">Other</a>	<a href="#">References</a>	<a href="#">Updates</a>			

### DESCRIPTION:

Serum tumor markers are molecules or substances shed by a tumor into the circulation where they can be detected and quantitated. Noncirculating tumor markers include those that can be detected histochemically or cytogenetically on a tissue sample.

Since serum tumor markers can also be detected in normal or benign lesions, significantly elevated circulating levels may occur with malignancy by one or more of the following mechanisms: overexpression of the antigen by malignant cells; a large tumor burden; or slower clearance of the marker. For example, since the liver clears most tumor markers, liver abnormalities (whether benign, malignant, or inflammatory) may elevate tumor marker concentrations due to impaired clearance. Because most tumor markers are not unique to malignancy, cut-off points must be established for normal versus abnormal marker levels.

The clinical applicability of tumor markers depends on how their measurements are used to influence the management of the patient and whether these management changes will result in an improvement in net health outcome.

### POSITION STATEMENT:

**Note:** Coverage may be governed by state or federal mandates.

<b>Biomarkers for Alzheimer Disease</b>	Cerebrospinal fluid biomarker testing, including but not limited to amyloid beta peptides, tau protein, or neural thread proteins, as an adjunct to clinical diagnosis in members with mild cognitive impairment or members with mild dementia due to Alzheimer disease is considered <b>experimental or investigational</b> . The evidence
---	---

<p>(AlzheimAlert™, ADmark® CSF, DISCERN™; PrecivityAD®)</p> <p><b>Note:</b> Genetic testing for Alzheimer disease (see MCG 05-82000-28) may be offered along with analysis of cerebral spinal fluid levels of the tau protein and amyloid-b peptide 1-42. This group of tests may be collectively referred to as the Admark™ Profile, offered by Athena Diagnostics.</p>	<p>is insufficient to determine the effects of the technology on health outcomes.</p> <p>Cerebrospinal fluid biomarker testing, including but not limited to amyloid beta peptides, tau protein, or neural thread proteins, as part of an evaluation for the initiation or continuation of amyloid beta targeting therapy in members with mild cognitive impairment or mild dementia due to Alzheimer disease is considered <b>experimental or investigational</b>. The evidence is insufficient to determine the effects of the technology on health outcomes.</p> <p>Measurement of urinary and blood biomarkers as an adjunct to clinical diagnosis in members with mild cognitive impairment or mild dementia due to Alzheimer disease is considered <b>experimental or investigational</b>. The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<p><b>Breast Tumor Markers</b></p>	<p>CA 15-3 (CA 27.29 or Truquant RIA) <b>meets the definition of medical necessity</b> for the following indications:</p> <ul style="list-style-type: none"> <li>• As an aid in the management of Stage II and Stage III breast cancer members. Serial testing for CA 15-3 assay values should be used in conjunction with other clinical methods for monitoring breast cancer</li> <li>• As an aid to predict recurrent breast cancer in members with previously treated Stage II or Stage III disease</li> <li>• As an aid in monitoring response to therapy in members with Stage IV breast cancer. A partial or complete response to treatment will be confirmed by declining levels. A persistent rise of CA 27-29 levels despite therapy strongly suggests progressive disease.</li> </ul> <p>CA 15-3 (CA 27.29 or Truquant RIA) is considered <b>experimental or investigational</b>, as there is insufficient clinical evidence to support the use of CA 15-3 (CA 27.29 or Truquant RIA) as a screening test for breast cancer. There is a lack of clinical data to permit conclusions on efficacy and net health outcomes.</p>

<p><b>Cancer Antigen 125 (CA-125)</b></p>	<p>CA-125 testing <b>meets the definition of medical necessity</b> in individuals with symptoms suggestive of ovarian cancer; symptoms may include:</p> <ul style="list-style-type: none"> <li>• Swelling of the abdomen (ascites)</li> <li>• Gastrointestinal symptoms (e.g., gas, bloating, long-term stomach pain, indigestion)</li> <li>• Bleeding between periods or after menopause</li> <li>• Pelvic pain</li> <li>• Feeling of pressure in the pelvis</li> <li>• Leg pain.</li> </ul> <p>CA-125 testing <b>meets the definition of medical necessity</b> in individuals with other gynecologic malignancies, such as endometrial cancer, in whom baseline levels of CA-125 have been shown to be elevated.</p> <p>CA-125 testing in asymptomatic individuals is considered <b>experimental or investigational</b>. There is insufficient clinical evidence to support the use of CA-125 testing as a screening technique for ovarian cancer.</p>
<p><b>Cardiovascular Disease Risk Panels</b></p> <p>(Cardiovascular risk panels may include: Applied Genetics Cardiac Panel; Boston Heart Advanced Risk Markers Panel; Cleveland HeartLab CVD Inflammatory Profile; Genetiks Genetic Diagnosis and Research Center Cardiovascular Risk Panel; Genova Diagnostics CV Health Plus Genomics™ Panel; Health Diagnostics Cardiac Risk Panel; Metametrix Cardiovascular Health Profile; MI-HEART Ceramides; Spectracell LPP™.)</p>	<p>Cardiovascular disease risk panels, consisting of multiple individual biomarkers intended to assess cardiac risk (other than simple lipid panels*), are considered <b>experimental or investigational</b>. The evidence is insufficient to determine the effects of the technology on health outcomes.</p> <p>*A simple lipid panel is generally composed of the following lipid measures: Total cholesterol; LDL cholesterol; HDL cholesterol; Triglycerides. Certain calculated ratios, such as the total/HDL cholesterol may also be reported as part of a simple lipid panel. Other types of lipid testing, i.e., apolipoproteins, lipid particle number or particle size, lipoprotein (a), etc., are not considered to be components of a simple lipid profile.</p>

<p><b>Gene Expression Profiling for Colorectal Cancer</b></p>	<p>Gene expression profiling (eg, ColonSentry<sup>®</sup>, BeScreened<sup>™</sup> - CRC) is considered <b>experimental or investigational</b> for colorectal cancer screening. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.</p>
<p><b>Tumor-Informed Circulating Tumor DNA</b></p>	<p>Tumor-informed circulating tumor DNA testing (e.g., Signatera<sup>™</sup>) is considered <b>experimental or investigational</b> for all indications. The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<p><b>Cutaneous Melanoma</b>  (DecisionDx DiffDx- Melanoma)</p>	<p>Gene expression testing, including but not limited to the Pigmented Lesion Assay (PLA), in the evaluation of members with suspicious pigmented lesions is considered <b>experimental or investigational</b>.</p> <p>Gene expression testing, including but not limited to the myPath Melanoma test, in the evaluation of members with melanocytic lesions with indeterminate histopathologic features is considered <b>experimental or investigational</b>.</p> <p>Gene expression testing, including but not limited to DecisionDx-Melanoma, in the evaluation of members with cutaneous melanoma is considered <b>experimental or investigational</b> for all indications.</p> <p>The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<p><b>Microarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification</b>  (MyPRS<sup>™</sup>/MyPRS Plus<sup>™</sup>)</p>	<p>Microarray-based gene expression profile testing for multiple myeloma is considered <b>experimental or investigational</b> for all indications. The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<p><b>Biomarker Testing, Including Liquid Biopsy (circulating tumor DNA/ctDNA), for Targeted Treatment and Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC)</b></p>	<p><b>EGFR Testing</b></p> <p>Analysis of tumor tissue for somatic variants in exons 18 through 21 (eg, G719X, L858R, T790M, S6781, L861Q) within the epidermal growth factor receptor (EGFR) gene, <b>meets the definition of medical necessity</b> to predict treatment response to an FDA-approved therapy (eg, erlotinib [Tarceva] alone or in combination with ramucirumab [Cyramza], gefitinib [Iressa], afatinib [Gilotrif], dacomitinib [Vizimpro], or osimertinib</p>

[Tagrisso]) in members with advanced lung adenocarcinoma, large cell carcinoma, advanced squamous-cell non-small-cell lung cancer (NSCLC), and NSCLC not otherwise specified.

Analysis of tumor tissue for somatic variants in exon 20 (eg, insertion mutations) within the EGFR gene, **meets the definition of medical necessity** to predict treatment response to an FDA-approved therapy (eg, mobocertinib [Exkivity] or amivantamab [Rybrevant]) in members with NSCLC.

At diagnosis, analysis of plasma for somatic variants in exons 19 through 21 (eg, exon 19 deletions, L858R, T790M ) within the EGFR gene, using the cobas EGFR Mutation Test v2, Guardant360 CDx test, FoundationOne Liquid CDx, OncoBEAM test, or InVisionFirst-Lung test to detect circulating tumor DNA (ctDNA), **meets the definition of medical necessity** as an alternative to tissue biopsy to predict treatment response to an FDA-approved therapy in members with advanced lung adenocarcinoma, large cell carcinoma, advanced squamous cell NSCLC, and NSCLC not otherwise specified.

At progression, analysis of plasma for the EGFR T790M resistance variant for targeted therapy with osimertinib using the cobas EGFR Mutation Test v2, Guardant360 CDx test, OncoBEAM test, or InVisionFirst-Lung test to detect ctDNA, **meets the definition of medical necessity** in members with advanced lung adenocarcinoma, large cell carcinoma, advanced squamous cell NSCLC, and NSCLC not otherwise specified, when tissue biopsy to obtain new tissue is not feasible (eg, in those who do not have enough tissue for standard molecular testing using formalin-fixed paraffin-embedded tissue, do not have a biopsy-amenable lesion, or cannot undergo biopsy).

Analysis of plasma for somatic variants in exon 20 (eg, insertion mutations) within the EGFR gene using an FDA-approved companion diagnostic plasma test to detect ctDNA **meets the definition of medical necessity** as an alternative to tissue biopsy to predict treatment response to an FDA-approved therapy in members with NSCLC (eg, amivantamab [Rybrevant]).

Analysis of somatic variants in the EGFR gene in tissue or plasma, including variants within exons 22 to 24, is considered **experimental or investigational** in all other situations. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

#### **ALK Testing**

Analysis of tumor tissue for somatic rearrangement variants of the anaplastic lymphoma kinase (ALK) gene in tissue **meets the definition of medical necessity** to predict treatment response to an FDA-approved ALK inhibitor therapy (eg, crizotinib [Xalkori], ceritinib [Zykadia], alectinib [Alecensa], brigatinib [Alunbrig], or lorlatinib [Lorbrena]) in members with advanced lung adenocarcinoma or in whom an adenocarcinoma component cannot be excluded.

Analysis of plasma for somatic rearrangement variants of the ALK gene using an FDA-approved companion diagnostic plasma test to detect ctDNA is **meets the definition of medical necessity** as an alternative to tissue biopsy to predict treatment response to an FDA-approved ALK inhibitor therapy in members with NSCLC (eg, alectinib [Alecensa]).

Analysis of somatic rearrangement variants of the ALK gene in tissue or plasma is considered **experimental or investigational** in all other situations. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

#### **BRAF V600E Testing**

Analysis of tumor tissue for the somatic BRAF V600E variant **meets the definition of medical necessity** to predict treatment response to an FDA-approved BRAF and/or MEK inhibitor therapy (eg, dabrafenib [Tafinlar] and trametinib [Mekinist]), in members with advanced lung adenocarcinoma or in whom an adenocarcinoma component cannot be excluded.

Analysis of tumor tissue for the somatic BRAF V600E variant is considered **experimental or investigational** in all other situations. The evidence is insufficient to

determine that the technology results in an improvement in the net health outcome.

Analysis of plasma for the somatic BRAF V600E variant to detect ctDNA is considered **experimental or investigational** as an alternative to tissue biopsy to predict treatment response to BRAF and/or MEK inhibitor therapy (eg, dabrafenib [Tafinlar], trametinib [Mekinist]) in members with NSCLC. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

#### **ROS1 Testing**

Analysis of tumor tissue for somatic rearrangement variants of the ROS1 gene **meets the definition of medical necessity** to predict treatment response to an FDA-approved ROS1 inhibitor therapy (eg, crizotinib [Xalkori] or entrectinib [Rozlytrek]) in members with advanced lung adenocarcinoma or in whom an adenocarcinoma component cannot be excluded.

Analysis of tumor tissue for somatic rearrangement variants of the ROS1 gene is considered **experimental or investigational** in all other situations. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Analysis of plasma for somatic rearrangement variants of the ROS1 gene to detect ctDNA is considered **experimental or investigational** as an alternative to tissue biopsy to predict treatment response to ROS1 inhibitor therapy (eg, crizotinib [Xalkori] or entrectinib [Rozlytrek]) in members with NSCLC. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

#### **KRAS Testing**

Analysis of tumor tissue for somatic variants of the KRAS gene (eg, G12C) **meets the definition of medical necessity** to predict treatment response to sotorasib (Lumakras) in members with advanced lung adenocarcinoma or in whom an adenocarcinoma component cannot be excluded.

Analysis of plasma for somatic variants of the KRAS gene (eg, G12C) using an FDA-approved companion diagnostic

plasma test to detect ctDNA **meets the definition of medical necessity** as an alternative to tissue biopsy to predict treatment response to sotorasib (Lumakras) in members with advanced lung adenocarcinoma or in whom an adenocarcinoma component cannot be excluded.

All other uses of analysis of somatic variants of the KRAS gene in tissue or plasma are considered **experimental or investigational**. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

#### **HER2 Testing**

Analysis of tumor tissue for somatic alterations in the HER2(ERBB2) gene may **meets the definition of medical necessity** to predict treatment response to an FDA-approved therapy (eg, fam-trastuzumab deruxtecan-nxki [Enhertu]) in members with unresectable or metastatic NSCLC.

Analysis of plasma for somatic alterations in the HER2(ERBB2) gene using an FDA-approved companion diagnostic plasma test to detect ctDNA **meets the definition of medical necessity** as an alternative to tissue biopsy to predict treatment response to an FDA-approved therapy (eg, fam-trastuzumab deruxtecan-nxki [Enhertu]) in members with unresectable or metastatic NSCLC.

All other uses of analysis of somatic variants of the HER2 (ERBB2) gene in tissue or plasma are considered **experimental or investigational**. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

#### **RET Rearrangement Testing**

Analysis of tumor tissue for somatic alterations in the RET gene **meets the definition of medical necessity** to predict treatment response to pralsetinib (Gavreto) or selpercatinib (Retevmo) in members with metastatic NSCLC.

Analysis of tumor tissue for somatic alterations in the RET gene is considered **experimental or investigational** in all other situations. The evidence is insufficient to determine



that the technology results in an improvement in the net health outcome.

Analysis of plasma for somatic alterations of the RET gene using plasma specimens to detect ctDNA is considered **experimental or investigational** as an alternative to tissue biopsy to predict treatment response to RET inhibitor therapy (eg, selpercatinib [Retevmo], pralsetinib [Gavreto]) in members with NSCLC. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

#### **MET Exon 14 Skipping Alteration**

Analysis of tumor tissue for somatic alterations in tissue that leads to MET exon 14 skipping **meets the definition of medical necessity** to predict treatment response to capmatinib (Tabrecta) in members with metastatic NSCLC.

Analysis of plasma for somatic alteration that leads to MET exon 14 skipping using an FDA-approved companion diagnostic plasma test to detect ctDNA **meets the definition of medical necessity** as an alternative to tissue biopsy to predict treatment response to MET inhibitor therapy (eg, capmatinib [Tabrecta]) in members with NSCLC.

All other uses of analysis of somatic variants of the MET gene in tissue or plasma are considered **experimental or investigational**. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

#### **PD-L1 Testing**

PD-L1 testing of tissue **meets the definition of medical necessity** to predict treatment response to an FDA-approved therapy (eg, atezolizumab [Tecentriq], nivolumab [Opdivo] in combination with ipilimumab [Yervoy], pembrolizumab [Keytruda], or cemiplimab-rwlc [Libtayo]) in members with NSCLC.

PD-L1 testing is considered **experimental or investigational** in all other situations. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

#### **Tumor Mutational Burden Testing**

	<p>Analysis of tumor mutational burden to predict treatment response to immunotherapy in individuals with NSCLC is considered <b>experimental or investigational</b>. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.</p> <p><b>Plasma Testing When Tissue is Insufficient</b></p> <p>Plasma tests for oncogenic driver variants deemed medically necessary on tissue biopsy <b>meets the definition of medical necessity</b> to predict treatment response to targeted therapy for members meeting the following criteria:</p> <ul style="list-style-type: none"> <li>• Member does not have sufficient tissue for standard molecular testing using formalin-fixed paraffin-embedded tissue; AND</li> <li>• Follow-up tissue-based analysis is planned should no driver variant be identified via plasma testing.</li> </ul>
<p><b>FDA Cleared or Approved Companion Diagnostic Devices</b></p>	<p>Biomarker identification <b>meets the definition of medical necessity</b> when confirmation is required per the “Indications and Usage” of the FDA-approved prescribing label prior to initiating therapy.</p> <p>List of Cleared or Approved Companion Diagnostic Devices can be found at: <a href="https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools">https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools</a></p>
<p><b>Molecular Markers in Fine Needle Aspirates of the Thyroid</b></p>	<p>For members who have thyroid nodules without strong clinical or radiologic findings suggestive of malignancy in whom surgical decision making would be affected by test results, the use of either of the following types of molecular marker testing or gene variant analysis in fine needle aspirates of thyroid nodules with indeterminate cytologic findings (ie, Bethesda diagnostic category III [atypia/follicular lesion of undetermined significance] or Bethesda diagnostic category IV [follicular neoplasm/suspicion for a follicular neoplasm]) <b>meets the definition of medical necessity</b>:</p> <ul style="list-style-type: none"> <li>• Afirma<sup>®</sup> Genomic Sequencing Classifier; or</li> <li>• ThyroSeq<sup>®</sup>.</li> </ul>

	<p>The use of any of the following types of molecular marker testing or gene variant analysis in fine needle aspirates of thyroid nodules with indeterminate findings (Bethesda diagnostic category III [atypia/follicular lesion of undetermined significance] or Bethesda diagnostic category IV [follicular neoplasm/suspicion for a follicular neoplasm]) or suspicious findings (Bethesda diagnostic category V [suspicious for malignancy]) to rule in malignancy to guide surgical planning for initial resection rather than a 2-stage surgical biopsy followed by definitive surgery <b>meets the definition of medical necessity</b>:</p> <ul style="list-style-type: none"> <li>• ThyroSeq;</li> <li>• ThyraMIR® microRNA/ThyGenX®;</li> <li>• Afirma BRAF after Afirma Genomic Sequencing Classifier; or</li> <li>• Afirma MTC after Afirma Genomic Sequencing Classifier.</li> </ul> <p>Gene expression classifiers, genetic variant analysis, and molecular marker testing in fine needle aspirates of the thyroid not meeting criteria outlined above, including but not limited to use of RosettaGX Reveal and single-gene TERT testing, are considered <b>experimental or investigational</b>. The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<b>Holo-Transcobalamin</b>	<p>Measurement of holo-transcobalamin, including but not limited to its use in the diagnosis and management of vitamin B12 deficiency, is considered <b>experimental or investigational</b>. There is insufficient clinical evidence to support the use of the measurement of holo-transcobalamin to identify early states of vitamin B12 deficiency. There are inadequate data to establish holo-TC testing as an alternative to either serum cobalamin or levels of MMA or homocysteine.</p>
<b>Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes</b>	<p>Measurement of long chain omega-3 fatty acids in red blood cell membranes is considered <b>experimental or investigational</b>, as there is insufficient clinical evidence to support the use of the measurement of long chain omega-3 fatty acids as a cardiac risk factor. There is a lack of scientific evidence in the published literature regarding</p>

	<p>how measurements of red blood cell omega-3 fatty acid would affect management of individuals at risk for or members with coronary artery disease (CAD).</p>
<p><b>Management of Pulmonary Nodules</b></p> <p>(Nodify CDT<sup>®</sup>, REVEAL Lung Nodule Characterization)</p>	<p>Plasma-based proteomic screening, including but not limited to BDX-XL2 (Nodify XL2<sup>®</sup>), in members with undiagnosed pulmonary nodules detected by computed tomography is considered <b>experimental or investigational</b>. The evidence is insufficient to determine the effects of the technology on health outcomes.</p> <p>Gene expression profiling on bronchial brushings, including but not limited to Percepta<sup>®</sup> Genomic Sequencing Classifier, in members with indeterminate bronchoscopy results from undiagnosed pulmonary nodules is considered <b>experimental or investigational</b>. The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<p><b>Measurement of Serum Antibodies to Selected Biologic Agents (e.g. infliximab, adalimumab, vedolizumab, or ustekinumab)</b></p> <p>(LabCorp<sup>®</sup> Adalimumab Concentration &amp; Anti-Adolimumab Antibody; Prometheus<sup>®</sup> Anser<sup>™</sup> IFX; Prometheus<sup>®</sup> Anser<sup>™</sup> ADA; Prometheus<sup>®</sup> Anser UST; Prometheus<sup>®</sup> Anser<sup>™</sup> VDZ )</p>	<p>Measurement of antidrug antibodies in a member receiving treatment with a biologic agent, either alone or as a combination test, which includes the measurement of serum TNF blocking agent levels, is considered <b>experimental or investigational</b>. There is insufficient evidence in medical literature regarding the clinical utility and impact on clinical outcomes to permit conclusions on net health outcomes.</p>
<p><b>Gene Expression-Based Assays for Cancers of Unknown Primary</b></p> <p>(CancerTYPE ID<sup>®</sup>, MiRview<sup>®</sup> tests, Tissue of Origin<sup>®</sup>, ProOnc TumorSource DX<sup>™</sup>, RosettaGX Cancer Origin<sup>™</sup> (formerly miRview<sup>®</sup> met<sup>2</sup>).</p>	<p>Gene expression profiling is considered <b>experimental or investigational</b> to evaluate the site of origin of a tumor of unknown primary, or to distinguish a primary from a metastatic tumor. The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<p><b>Multianalyte Assays for Chronic Liver Disease</b></p>	<p>A single FibroSURE<sup>®</sup> multianalyte assay <b>meets the definition of medical necessity</b> for the evaluation of members with chronic liver disease.</p>

	<p>FibroSURE® multianalyte assays are considered <b>experimental or investigational</b> for monitoring members with chronic liver disease. The evidence is insufficient to determine the effects of the technology on health outcomes.</p> <p>The use of other multianalyte assays with algorithmic analyses (e.g. FIBROSpect® II) is considered <b>experimental or investigational</b> for the evaluation or monitoring of members with chronic liver disease. The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<p><b>Multibiomarker Disease Activity Score for Rheumatoid Arthritis</b> (Prism™ RA)</p>	<p>The use of a multibiomarker disease activity score for rheumatoid arthritis (eg, Vectra® score) is considered <b>experimental or investigational</b> in all situations. The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<p><b>Multicancer Early Detection Testing</b></p>	<p>The use of multicancer early detection (MCED) tests (e.g. Galleri®) is considered <b>experimental or investigational</b> for cancer screening. The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<p><b>Multimarker Serum Testing Related to Ovarian Cancer</b></p>	<p>All uses of the OVA1®, Overa™, OvaWatch<sup>sm</sup>, and ROMA™ tests are considered <b>experimental or investigational</b>, including but not limited to:</p> <ul style="list-style-type: none"> <li>• preoperative evaluation of adnexal masses to triage for malignancy</li> <li>• screening for ovarian cancer</li> <li>• selecting members for surgery for an adnexal mass</li> <li>• evaluation of members with clinical or radiologic evidence of malignancy</li> <li>• evaluation of members with nonspecific signs or symptoms suggesting possible malignancy, or</li> <li>• postoperative testing and monitoring to assess surgical outcome and/or to detect recurrent malignant disease following treatment.</li> </ul> <p>The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<p><b>Pharmacogenomic and Metabolite Markers for</b></p>	<p>One-time genotypic or phenotypic analysis of thiopurine methyltransferase (TPMT) and nudix hydrolase (NUDT15)</p>

<p><b>Members Treated with Thiopurines</b></p>	<p><b>meets the definition of medical necessity</b> in members beginning therapy with azathioprine (AZA), mercaptopurine (6-MP), thioguanine, or in members on thiopurine therapy with abnormal complete blood count (CBC) results that do not respond to dose reduction.</p> <p>Genotypic and/or phenotypic analysis of TPMT and NUDT15 is considered <b>experimental or investigational</b> for all other indications. The evidence is insufficient to determine the effects of technology on net health outcomes.</p> <p>Analysis of the metabolite markers of azathioprine (AZA) and mercaptopurine (6-MP), including 6-methyl-mercaptopurine ribonucleotides (6-MMRP) and 6-thioguanine nucleotides (6-TGN), is considered <b>experimental or investigational</b>. The evidence is insufficient to determine the effects of technology on net health outcomes.</p>
<p><b>Proteogenomic Testing for Members With Cancer</b></p>	<p>Proteogenomic testing of members with cancer (including but not limited to GPS Cancer™ test) is considered <b>experimental or investigational</b> for all indications. The evidence is insufficient to determine the effect of the technology on health outcomes.</p>
<p><b>Proteomic Testing for Advanced Non-Small Cell Lung Cancer (NSCLC)</b></p>	<p>Proteomic testing (VeriStrat®) <b>meets the definition of medical necessity</b> for members with advanced non-small cell lung cancer (NSCLC) meeting <b>ALL</b> of the following criteria:</p> <ul style="list-style-type: none"> <li>• tumor is wild-type (no mutation detected) EGFR <b>OR</b> with unknown EGFR status;</li> <li>• failed first-line systemic chemotherapy; <b>AND</b></li> <li>• test results will determine whether to proceed with erlotinib (Tarceva®) therapy.</li> </ul> <p>Proteomic testing (VeriStrat) is considered <b>experimental or investigational</b> for all other indications. There is insufficient evidence to permit conclusions on clinical utility or net health outcomes.</p>
<p><b>Serum Biomarker Human Epididymis Protein 4</b></p> <p>(Architect HE4 assay, Elecsys HE4, HE4 EIA Kit, HE4</p>	<p>Measurement of human epididymis protein 4 (HE4) is considered <b>experimental or investigational</b> for all indications. The evidence is insufficient to determine the effects of the technology on health outcomes.</p>

immunoassay, Lumipulse G HE4 Immunoreaction)	
<p><b>Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases</b></p> <p>(Avisé<sup>®</sup> CTD, Avisé<sup>®</sup> Lupus, Avisé<sup>®</sup> Monitor, Avisé<sup>®</sup> MTX, Avisé<sup>®</sup>, PG, Avisé<sup>®</sup> Prognostic, Avisé<sup>®</sup> SLE, Avisé<sup>®</sup> SLE+)</p>	<p>Serum biomarker panel testing with proprietary algorithms and/or index scores for the diagnosis of systemic lupus erythematosus is considered <b>experimental or investigational</b>. The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<p><b>Serum Biomarker Tests for Multiple Sclerosis</b></p>	<p>Serum biomarker tests (e.g. gMS<sup>®</sup> Dx, gMS<sup>®</sup> Pro EDSS) for multiple sclerosis are considered <b>experimental or investigational</b> for all indications. There is insufficient evidence from prospective studies demonstrating improved health outcomes in individuals who may have multiple sclerosis and who are treated according to test results.</p>
<p><b>Uveal Melanoma</b></p>	<p>Gene expression profiling for uveal melanoma with DecisionDx-UM <b>meets the definition of medical necessity</b> for members with primary, localized uveal melanoma.</p> <p>Gene expression profiling for uveal melanoma that do not meet the above criteria is considered <b>experimental or investigational</b>. The evidence is insufficient to determine the effects of the technology on health outcomes.</p>

The following tumor markers are considered **experimental or investigational** for all indications, as there is insufficient evidence in the peer reviewed medical literature to support the use of these markers for screening, diagnosing, staging, surveillance or monitoring response to treatment:

**Table 1**

<u>a2-PAG</u>	pregnancy-associated alpha-2-glycoprotein
<u>BCM</u>	breast cancer mucin
CA50	cancer antigen 50
CA72-4	cancer antigen 72-4
CA195	cancer antigen 195
CA242	cancer antigen 242
CA549	carbohydrate antigen/cancer antigen 594
CA-SCC	squamous cell carcinoma antigen
<u>CAM17-1</u>	monocolonal antimucin antibody 17-1
<u>CAM-26</u>	monocolonal antimucin antibody 26

<u>CAM-29</u>	monocolonal antimucin antibody 29
<u>CAR-3</u>	antigenic determinant recognized by monoclonal antibody AR-3
<u>DU-PAN-2</u>	sialylated carbohydrate antigen DU-PAN-2
<u>MCA</u>	mucin-like carcinoma-associated antigen
<u>NSE</u>	neuron-specific enolase
<u>P-LAP</u>	placental alkaline phosphatase
<u>PNA/ELLA</u>	peanut lectin bonding assay
<u>SLEX</u>	sialylated Lewis X-I antigen
<u>SLX</u>	sialylated SSEA-1 antigen
<u>SPAN-1</u>	sialylated carbohydrate antigen SPAN-1
<u>ST-439</u>	sialylated carbohydrate antigen ST-439
<u>TAG12</u>	tumor-associated glycoprotein 12
<u>TAG72</u>	tumor-associated glycoprotein 72
<u>TAG72.3</u>	tumor-associated glycoprotein 72.3
<u>TATI</u>	tumor-associated trypsin inhibitor
<u>TNF-a</u>	tumor necrosis factor alpha
<u>TPA</u>	tissue polypeptic antigen

Home testing (including self-testing home kits) is considered **experimental or investigational** for all indications. The clinical validity of the tests have not been established and the evidence is insufficient to determine the effects of the technology on health outcomes.

**The following tests are considered experimental or investigational**, as there is insufficient evidence to support the use of these tests for all indications. Although there are ongoing clinical studies the current data are inadequate to permit scientific conclusions regarding the impact on management decisions and net health outcomes.

- Academic Profile
- Avise MCV
- CellSearch® Circulating Multiple Myeloma Cell
- CellSearch® HER2 Circulating Tumor Cell
- Cxbladder™/Cxbladder Detect
- Darwin OncoTreat™ (formerly OncoTreat)
- Decipher® Bladder TURBT
- DetermaRx™ mRNA
- FiT IQ™
- GeneSearch™ BLNHeproDx-TM
- Guardant360 TissueNext™
- HERmark®
- InflammDry®
- KidneyIntelX™
- LC-MS/MS Targeted
- MI Cancer Seek™
- MSK-Impact™
- NETest



- OncoExTra™ (formerly Oncomap ExTra and GEM ExTra)
- Oncomap™ (formerly Oncotype MAP)
- Ova Check™
- OvaSure™
- PathwayFit®
- PGDx elio™ Tissue Complete
- PharmaRisk™
- Post-Op Px™ (previously known as ProstatePX)
- Praxis Extended RAS Panel
- PreDx Diabetes Risk Score™
- Prostate Px+
- ResponseDX: Lung™
- ResponseDX: Colon™
- Thyroid Cancer Mutation Panel.

## BILLING/CODING INFORMATION:

### Afirma® Genomic Sequencing Classifier

#### CPT Coding

81546	Oncology (thyroid), mRNA, gene expression analysis of 10,196 genes, utilizing fine needle aspirate, algorithm reported as a categorical result (eg, benign or suspicious)
-------	---

#### ICD-10 Diagnosis Codes That Support Medical Necessity (81545)

C73	Malignant neoplasm of thyroid gland
D44.0	Neoplasm of uncertain behavior of thyroid gland

### AVISE Lupus

#### CPT Coding

0312U	Autoimmune diseases (eg, systemic lupus erythematosus [SLE]), analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using enzyme-linked immunosorbent immunoassay (ELISA), flow cytometry and indirect immunofluorescence, serum, or plasma and whole blood, individual components reported along with an algorithmic SLE-likelihood assessment <b>(Investigational)</b>
-------	---

### BeScreened™-CRC

#### CPT Coding

0163U	Oncology (colorectal) screening, biochemical enzyme-linked immunosorbent assay (ELISA) of 3 plasma or serum proteins
-------	--

	(teratocarcinoma derived growth factor-1 [TDGF-1, Cripto-1], carcinoembryonic antigen [CEA], extracellular matrix protein [ECM]), with demographic data (age, gender, CRC-screening compliance) using a proprietary algorithm and reported as likelihood of CRC or advanced adenomas <b>(Investigational)</b>
--	---

### **Biochemical Markers of Alzheimer’s Disease**

#### **CPT Coding**

0206U	Neurology (Alzheimer disease); cell aggregation using morphometric imaging and protein kinase C-epsilon (PKCe) concentration in response to amylospheroid treatment by ELISA, cultured skin fibroblasts, each reported as positive or negative for Alzheimer disease <b>(Investigational)</b>
0207U	Neurology (Alzheimer disease); cell aggregation using morphometric imaging and protein kinase C-epsilon (PKCe) concentration in response to amylospheroid treatment by ELISA, quantitative imaging of phosphorylated ERK1 and ERK2 in response to bradykinin treatment by in situ immunofluorescence, using cultured skin fibroblasts, reported as a probability index for Alzheimer disease (List separately in addition to code for primary procedure) <b>(Investigational)</b>

### **BRAF**

#### **CPT Coding**

81210	BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, colon cancer, melanoma), gene analysis, V600 variant(s)
-------	---

### **Breast Tumor Markers**

#### **CPT Coding**

86300	Immunoassay for tumor antigen, Quantitative; CA 15-3 (27.29)
-------	--

### **ICD-10 Diagnosis Codes That Support Medical Necessity (86300)**

C50.011 – C50.929	Malignant neoplasm of breast
C79.2	Secondary malignant neoplasm of skin
C79.81	Secondary malignant neoplasm of breast
G89.3	Neoplasm related pain (acute) (chronic)
R97.8	Other abnormal tumor markers
Z85.3	Personal history of malignant neoplasm of breast

### **Cancer Antigen 125 (CA-125)**

## CPT Coding

86304	Immunoassay for tumor antigen, CA-125
-------	---------------------------------------

## ICD-10 Diagnosis Codes That Support Medical Necessity (86304)

C45.1	Mesothelioma of peritoneum
C48.1	Malignant neoplasm of specified parts of peritoneum
C48.2	Malignant neoplasm of peritoneum, unspecified
C48.8	Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum
C53.0	Malignant neoplasm of endocervix
C53.1	Malignant neoplasm of exocervix
C54.1 – C54.9	Malignant neoplasm of corpus uteri
C56.1 – C56.9	Malignant neoplasm of ovary
C57.00 – C57.9	Malignant neoplasm of other and unspecified female genital organs
C79.60	Secondary malignant neoplasm of ovary, unspecified side
C79.61	Secondary malignant neoplasm of right ovary
C79.62	Secondary malignant neoplasm of left ovary
C79.82	Secondary malignant neoplasm of genital organs
C79.89	Secondary malignant neoplasm of other specified sites
D39.0 D39.10 – D39.12 D39.7 – D39.9	Neoplasm of uncertain behavior of female genital organs
G89.3	Neoplasm related pain (acute) (chronic)
R19.00	Intra-abdominal and pelvic swelling, mass and lump, unspecified site
R19.01	Right upper quadrant abdominal swelling, mass and lump
R19.02	Left upper quadrant abdominal swelling, mass and lump
R19.03	Right lower quadrant abdominal swelling, mass and lump
R19.04	Left lower quadrant abdominal swelling, mass and lump
R19.05	Periumbilical swelling, mass or lump
R19.06	Epigastric swelling, mass or lump
R19.07	Generalized intra-abdominal and pelvic swelling, mass and lump
R19.09	Other intra-abdominal and pelvic swelling, mass and lump
R97.1	Elevated cancer antigen 125 [CA 125]
R97.8	Other abnormal tumor markers
Z85.40	Personal history of malignant neoplasm of unspecified female genital organ
Z85.41	Personal history of malignant neoplasm of cervix uteri
Z85.42	Personal history of malignant neoplasm of other parts of uterus
Z85.43	Personal history of malignant neoplasm of ovary
Z85.44	Personal history of malignant neoplasm of other female genital organs

### CPT Coding

81540	Oncology (tumor of unknown origin), mRNA, gene expression profiling by real-time RT-PCR of 92 genes (87 content and 5 housekeeping) to classify tumor into main cancer type and subtype, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a probability of a predicted main cancer type and subtype <b>(Investigational)</b>
-------	--

### Cardiovascular Risk Panel: MI-HEART Ceramides

### CPT Coding

0119U	Cardiology, ceramides by liquid chromatography-tandem mass spectrometry, plasma, quantitative report with risk score for major cardiovascular events <b>(Investigational)</b>
-------	---

### Caris MI Cancer Seek

### CPT Coding

0211U	Oncology (pan-tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded tissue, interpretative report for single nucleotide variants, copy number alterations, tumor mutational burden, and microsatellite instability, with therapy association <b>(Investigational)</b>
-------	---

### CellSearch® Circulating Multiple Myeloma Cell

### CPT Coding

0337U	Oncology (plasma cell disorders and myeloma), circulating plasma cell immunologic selection, identification, morphological characterization, and enumeration of plasma cells based on differential CD138, CD38, CD19, and CD45 protein biomarker expression, peripheral blood <b>(Investigational)</b>
-------	--

### CellSearch® HER2 Circulating Tumor Cell

### CPT Coding

0338U	Oncology (solid tumor), circulating tumor cell selection, identification, morphological characterization, detection and enumeration based on differential EpCAM, cytokeratins 8, 18, and 19, and CD45 protein biomarkers, and quantification of HER2 protein biomarker-expressing cells, peripheral blood <b>(Investigational)</b>
-------	--

### Cutaneous Melanoma

## CPT Coding

0089U	Oncology (melanoma), gene expression profiling by RTqPCR, PRAME and LINC00518, superficial collection using adhesive patch(es) ( <b>Investigational</b> )
0090U	Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, indeterminate, malignant) ( <b>Investigational</b> )

## Cxbladder™

### CPT Coding

0012M	Oncology (urothelial), mRNA, gene expression profiling by real-time quantitative PCR of five genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and XCR2), utilizing urine, algorithm reported as a risk score for having urothelial carcinoma ( <b>Investigational</b> )
0013M	Oncology (urothelial), mRNA, gene expression profiling by real-time quantitative PCR of five genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and CXCR2), utilizing urine, algorithm reported as a risk score for having recurrent urothelial carcinoma ( <b>Investigational</b> )
0363U	Oncology (urothelial), mRNA, gene expression profiling by real-time quantitative PCR of 5 genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and CXCR2), utilizing urine, algorithm incorporates age, sex, smoking history, and macrohematuria frequency, reported as a risk score for having urothelial carcinoma ( <b>Investigational</b> )

## Cxbladder™ Detct

### CPT Coding

0420U	Oncology (urothelial), mRNA expression profiling by real-time quantitative PCR of MDK, HOXA13, CDC2, IGFBP5, and CXCR2 in combination with droplet digital PCR (ddPCR) analysis of 6 single-nucleotide polymorphisms (SNPs) genes TERT and FGFR3, urine, algorithm reported as a risk score for urothelial carcinoma ( <b>Investigational</b> )
-------	---

## Darwin OncoTreat

### CPT Coding

0019U	Oncology, RNA, gene expression by whole transcriptome sequencing, formalin-fixed paraffin embedded tissue or fresh frozen tissue, predictive algorithm reported as potential targets for therapeutic agents ( <b>Investigational</b> )
-------	--

## Decipher Bladder TURBT

### CPT Coding

0016M	Oncology (bladder), mRNA, microarray gene expression profiling of 219 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as molecular subtype (luminal, luminal infiltrated, basal, basal claudin-low, neuroendocrine-like) <b>(Investigational)</b>
-------	--

### DecisionDx DiffDx- Melanoma

### CPT Coding

0314U	Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 35 genes (32 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant) <b>(Investigational)</b>
-------	--

### DecisionDx-Melanoma

### CPT Coding

81529	Oncology (cutaneous melanoma), mRNA, gene expression profiling by real-time RT-PCR of 31 genes (28 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk, including likelihood of sentinel lymph node metastasis <b>(Investigational)</b>
-------	---

### DecisionDx-UM

### CPT Coding

81552	Oncology (uveal melanoma), mRNA, gene expression profiling by real-time RT-PCR of 15 genes (12 content and 3 housekeeping), utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue, algorithm reported as risk of metastasis
-------	---

### ICD-10 Diagnosis Codes That Support Medical Necessity (81552)

C69.00-C69.92	Malignant neoplasm of eye and adnexa
---------------	--------------------------------------

### DetermarX mRNA

### CPT Coding

0288U	Oncology (lung), mRNA, quantitative PCR analysis of 11 genes (BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A) and 3 reference genes (ESD, TBP, YAP1), formalin-fixed paraffin-embedded (FFPE) tumor tissue, algorithmic interpretation reported as a recurrence risk score <b>(Investigational)</b>
-------	--

## Elecsys® PhosphoTau (181P) CSF (pTau181) and βAmyloid (1-42) CSF II (Abeta 42) Ratio

### CPT Coding

0445U	β-amyloid (Abeta42) and phosphor tau (181P) (pTau181), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology <b>(Investigational)</b>
-------	--

## Epidermal Growth Factor Receptor (EGFR) Analysis

### CPT Coding

81235	EGFR (epidermal growth factor receptor) (e.g., non-small cell lung cancer) gene analysis, common variants (e.g., exon 19 LREA deletion, L858R, T790M, G719A, G719S, L861Q)
-------	--

## FoundationOne® CDx

### CPT Coding

0037U	Targeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden
-------	--

## FoundationOne® Liquid CDx

### CPT Coding

0239U	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free DNA, analysis of 311 or more genes, interrogation for sequence variants, including substitutions, insertions, deletions, select rearrangements, and copy number variations
-------	--

## Guardant360 CDx

### CPT Coding

0242U	Targeted genomic sequence analysis panel, solid organ neoplasm, cell free circulating DNA analysis of 55-74 genes, interrogation for sequence variants, gene copy number amplifications, and gene rearrangements
-------	--

## Guardant360 TissueNext

### CPT Coding

0334U	Oncology (solid organ), targeted genomic sequence analysis, formalin-fixed paraffin-embedded (FFPE) tumor tissue, DNA analysis, 84 or more genes,
-------	---

	interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden <b>(Investigational)</b>
--	--

### **HeproDx-TM**

#### **CPT Coding**

0006M	Oncology (hepatic), mRNA expression levels of 161 genes, utilizing fresh hepatocellular carcinoma tumor tissue, with alpha-fetoprotein level, algorithm reported as a risk classifier <b>(Investigational)</b>
-------	--

### **InflammaDry®**

InflammaDry® may be reported with CPT code 83516-Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method.

### **KidneyIntelX™**

#### **CPT Coding**

0105U	Nephrology (chronic kidney disease), multiplex electrochemiluminescent immunoassay (ECLIA) of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) combined with longitudinal clinical data, including APOL1 genotype if available, and plasma (isolated fresh or frozen), algorithm reported as probability score for rapid kidney function decline (RKFD) <b>(Investigational)</b>
-------	--

### **KRAS Testing**

#### **CPT Coding**

81275	KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; variants in exon 2 (eg, codons 12 and 13)
81276	KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; additional variant(s) (eg, codon 61, codon 146)

### **LC-MS/MS Targeted Proteomic**

#### **CPT Coding**

0174U	Oncology (solid tumor), mass spectrometric 30 protein targets, formalin-fixed paraffin-embedded tissue, prognostic and predictive algorithm reported as likely, unlikely, or uncertain benefit of 39 chemotherapy and targeted therapeutic oncology agents <b>(Investigational)</b>
-------	---

### **Measurement of Serum Antibodies to Selected Biologic Agents**



### CPT Coding

80145	Adalimumab ( <b>Investigational</b> )
80230	Infliximab ( <b>Investigational</b> )
80280	Vedolilzumab ( <b>Investigational</b> )

### MSK-Impact

### CPT Coding

0048U	Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s) ( <b>Investigational</b> )
-------	--

### OncoExTra

### CPT Coding

0329U	Oncology (neoplasia), exome and transcriptome sequence analysis for sequence variants, gene copy number amplifications and deletions, gene rearrangements, microsatellite instability and tumor mutational burden utilizing DNA and RNA from tumor with DNA from normal blood or saliva for subtraction, report of clinically significant mutation(s) with therapy associations ( <b>Investigational</b> )
-------	--

### Oncomap

### CPT Coding

0244U	Oncology (solid organ), DNA, comprehensive genomic profiling, 257 genes, interrogation for single-nucleotide variants, insertions/deletions, copy number alterations, gene rearrangements, tumor-mutational burden and microsatellite instability, utilizing formalin-fixed paraffin-embedded tumor tissue ( <b>Investigational</b> )
-------	---

### Circulating Tumor Cells/Liquid Biopsy

### CPT Coding

86152	Cell enumeration using immunologic selection and identification in fluid specimen (eg, circulating tumor cells in blood) ( <b>Investigational</b> )
86153	Cell enumeration using immunologic selection and identification in fluid specimen (eg, circulating tumor cells in blood); physician interpretation and report, when required ( <b>Investigational</b> )

0009U	Oncology (breast cancer), ERBB2 (HER2) copy number by FISH, tumor cells from formalin fixed paraffin embedded tissue isolated using image-based dielectrophoresis (DEP) sorting, reported as ERBB2 gene amplified or non-amplified <b>(Investigational)</b>
0091U	Oncology (colorectal) screening, cell enumeration of circulating tumor cells, utilizing whole blood, algorithm, for the presence of adenoma or cancer, reported as a positive or negative result <b>(Investigational)</b>
0179U	Oncology (non-small cell lung cancer), cell free DNA, targeted sequence analysis of 23 genes [single nucleotide variations, insertions and deletions, fusions without prior knowledge of partner/breakpoint, copy number variations], with report of significant mutation(s) <b>(Investigational)</b>

### OVA1®

#### CPT Coding

81503	Oncology (ovarian), biochemical assays of five proteins (CA-125, apolipoprotein A1, beta-2 microglobulin, transferrin and pre-albumin), utilizing serum, algorithm reported as a risk score <b>(Investigational)</b>
-------	--

### OvaWatch<sup>sm</sup>

#### CPT Coding

0375U	Oncology (ovarian), biochemical assays of 7 proteins (follicle stimulating hormone, human epididymis protein 4, apolipoprotein A-1, transferrin, beta-2 macroglobulin, prealbumin [ie, transthyretin], and cancer antigen 125), algorithm reported as ovarian cancer risk score <b>(Investigational)</b>
-------	--

### Overa™

#### CPT Coding

0003U	Oncology (ovarian) biochemical assays of five proteins (apolipoprotein A-1, CA 125 II, follicle stimulating hormone, human epididymis protein 4, transferrin), utilizing serum, algorithm reported as a likelihood score <b>(Investigational)</b>
-------	---

### HE4 immunoassays & Kits

#### CPT Coding

86305	Human epididymis protein 4 (HE4) <b>(Investigational)</b>
-------	---

### Management of Pulmonary Nodules

## CPT Coding

81554	Pulmonary disease (idiopathic pulmonary fibrosis [IPF]), mRNA, gene expression analysis of 190 genes, utilizing transbronchial biopsies, diagnostic algorithm reported as categorical result (eg, positive or negative for high probability of usual interstitial pneumonia [UIP]) <b>(Investigational)</b>
0080U	Oncology (lung), mass spectrometric analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein M130, with five clinical risk factors (age, smoking status, nodule diameter, nodule-spiculation status and nodule location), utilizing plasma, algorithm reported as a categorical probability of malignancy <b>(Investigational)</b>
0092U	Oncology (lung), three protein biomarkers, immunoassay using magnetic nanosensor technology, plasma, algorithm reported as risk score for likelihood of malignancy <b>(Investigational)</b>
0360U	Oncology (lung), enzyme-linked immunosorbent assay (ELISA) of 7 autoantibodies (p53, NY-ESO-1, CAGE, GBU4-5, SOX2, MAGE A4, and HuD), plasma, algorithm reported as a categorical result for risk of malignancy <b>(Investigational)</b>

## Multianalyte Assays for Chronic Liver Disease

### CPT Coding

81517	Liver disease, analysis of 3 biomarkers (hyaluronic acid [HA], procollagen III amino terminal peptide [PIIINP], tissue inhibitor of metalloproteinase 1 [TIMP-1]), using immunoassays, utilizing serum, prognostic algorithm reported as a risk score and risk of liver fibrosis and liver-related clinical events within 5 years <b>(Investigational)</b>
81596	Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver
0002M	Liver disease, ten biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, haptoglobin, AST, glucose, total cholesterol and triglycerides) utilizing serum, prognostic algorithm reported as quantitative scores for fibrosis, steatosis and alcoholic steatohepatitis (ASH)
0003M	Liver disease, ten biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, haptoglobin, AST, glucose, total cholesterol and triglycerides) utilizing serum, prognostic algorithm reported as quantitative scores for fibrosis, steatosis and nonalcoholic steatohepatitis (NASH)

0166U	Liver disease, 10 biochemical assays ( $\alpha$ 2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, GGT, ALT, AST, triglycerides, cholesterol, fasting glucose) and biometric and demographic data, utilizing serum, algorithm reported as scores for fibrosis, necroinflammatory activity, and steatosis with a summary interpretation <b>(Investigational)</b>
-------	--

### **NETest**

#### **CPT Coding**

0007M	Oncology (gastrointestinal neuroendocrine tumors), real-time PCR expression analysis of 51 genes, utilizing whole peripheral blood, algorithm reported as a nomogram of tumor disease index <b>(Investigational)</b>
-------	--

### **NTRK Gene Fusion Testing**

#### **CPT Coding**

81191	NTRK1 (neurotrophic receptor tyrosine kinase 1) (eg, solid tumors) translocation analysis
81192	NTRK2 (neurotrophic receptor tyrosine kinase 2) (eg, solid tumors) translocation analysis
81193	NTRK3 (neurotrophic receptor tyrosine kinase 3) (eg, solid tumors) translocation analysis
81194	NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis

### **Pathwork Tissue of Origin®**

#### **CPT Coding**

81504	Oncology (tissue of origin), microarray gene expression profiling of > 2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores <b>(Investigational)</b>
-------	---

### **PGDx elio Tissue Complete**

#### **CPT Coding**

0250U	Oncology (solid organ neoplasm), targeted genomic sequence DNA analysis of 505 genes, interrogation for somatic alterations (SNVs [single nucleotide variant], small insertions and deletions, one amplification, and four translocations), microsatellite instability and tumor-mutation burden <b>(Investigational)</b>
-------	---

### **Pharmacogenomic and Metabolite Markers for Members Treated With Thiopurines**

### CPT Coding

81335	TPMT (thiopurine S-methyltransferase) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3)
84433	Thiopurine S-methyltransferase (TPMT)
0034U	TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; NUDT15 *3, *4, *5)
0169U	NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) (eg, drug metabolism) gene analysis, common variants

### ICD-10 Diagnosis Codes That Support Medical Necessity (81335, 0034U, 0169U))

K50.00-K50.019	Crohn's disease of small intestine
K51.00-K51.319	Ulcerative colitis

### Praxis Extended RAS Panel

### CPT Coding

0111U	Oncology (colon cancer), targeted KRAS (codons 12, 13, and 61) and NRAS (codons 12, 13, and 61) gene analysis utilizing formalin-fixed paraffin-embedded tissue <b>(Investigational)</b>
-------	--

### PreDx Diabetes Risk Score™

### CPT Coding

81506	Endocrinology (type 2 diabetes), biochemical assays of seven analytes (glucose, HbA1c, insulin, hs-CRP, adiponectin, ferritin, interleukin 2-receptor alpha), utilizing serum or plasma, algorithm reporting a risk score (Investigational)
-------	---

### PrecivityAD

### CPT Coding

0412U	Beta amyloid, A $\beta$ 42/40 ratio, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and qualitative ApoE isoformspecific proteotyping, plasma combined with age, algorithm reported as presence or absence of brain amyloid pathology <b>(Investigational)</b>
-------	---

### ROMA™

## CPT Coding

81500	Oncology (ovarian), biochemical assays of two proteins (CA-125 and HE4), utilizing serum, with menopausal status, algorithm reported as a risk score <b>(Investigational)</b>
86316**	Immunoassay for tumor antigen; other antigen, quantitative (e.g., CA 50, 72-4, 549), each <b>(Investigational)</b>

**\*\*May be covered when meets the definition of medical necessity when used to report the Chromogranin A (CgA) test for neuroendocrine tumors (i.e. carcinoid tumors).**

## Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases

### CPT Coding

0062U	Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score <b>(Investigational)</b>
-------	--

## Signatera™

### CPT Coding

0340U	Oncology (pan-cancer), analysis of minimal residual disease (MRD) from plasma, with assays personalized to each patient based on prior next-generation sequencing of the patient's tumor and germline DNA, reported as absence or presence of MRD, with disease-burden correlation, if appropriate <b>(Investigational)</b>
-------	---

## TERT Testing

### CPT Coding

81345	TERT (telomerase reverse transcriptase) (eg, thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (eg, promoter region) <b>(Investigational)</b>
-------	---

## ThyGeNEXT®

### CPT Coding

0245U	Oncology (thyroid), mutation analysis of 10 genes and 37 RNA fusions and expression of 4 mRNA markers using next generation sequencing, fine needle aspirate, report includes associated risk of malignancy expressed as a percentage
-------	---

## ThyraMIR™

### CPT Coding

0018U	Oncology (thyroid), microRNA profiling by RT-PCR of 10 microRNA sequences, utilizing fine needle aspirate, algorithm reported as a positive or negative result for moderate to high risk of malignancy
-------	--

### ICD-10 Diagnosis Codes That Support Medical Necessity (0018U)

C73	Malignant neoplasm of thyroid gland
D44.0	Neoplasm of uncertain behavior of thyroid gland

### Thyroseq®

### CPT Coding

0026U	Oncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result (“Positive, high probability of malignancy” or “Negative, low probability of malignancy”)
-------	--

### ICD-10 Diagnosis Codes That Support Medical Necessity (0026U)

C73	Malignant neoplasm of thyroid gland
D44.0	Neoplasm of uncertain behavior of thyroid gland

### Thyroseq® CRC

### CPT Coding

0287U	Oncology (thyroid), DNA and mRNA, next generation sequencing analysis of 112 genes, fine needle aspirate or formalin-fixed paraffin-embedded (FFPE) tissue, algorithmic prediction of cancer recurrence, reported as a categorical risk result (low, intermediate, high) <b>(Investigational)</b>
-------	---

### Vectra®

### CPT Coding

81490	Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score <b>(Investigational)</b>
-------	--

### VeriStrat®

### CPT Coding

81538	Oncology (lung), mass spectrometric 8-protein signature, including amyloid A, utilizing serum, prognostic and predictive algorithm reported as good versus poor overall survival
-------	--

## ICD-10 Diagnosis Codes That Support Medical Necessity (81538)

C34.00 – C34.92	Malignant neoplasm of bronchus and lung
-----------------	---

Tumor markers that do not have a specific CPT or HCPCS code may be reported with a nonspecific code such as CPT code 86316.

### REIMBURSEMENT INFORMATION:

The following information is required documentation to support medical necessity: physician history and physical, physician progress notes, laboratory studies, treatment plan, and physician operative report (if applicable).

### LOINC Codes

Documentation Table	LOINC Codes	LOINC Time Frame Modifier Code	LOINC Time Frame Modifier Codes Narrative
Physician history and physical	28626-0	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim
Attending physician progress note	18741-9	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.
Plan of treatment	18776-5	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.
Laboratory studies	26436-6	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim
Physician operative report	28573-4	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim

### PROGRAM EXCEPTIONS:

**Federal Employee Program (FEP):** Follow FEP guidelines.

**State Account Organization (SAO):** Follow SAO guidelines.

**Medicare Advantage Products:**



The following National Coverage Determinations (NCD) were reviewed on the last guideline reviewed date and located at cms.gov: Tumor Antigen by Immunoassay-CA 125 (190.28); Tumor Antigen by Immunoassay-CA 15-3/CA 27.29 (190.29); Tumor Antigen by Immunoassay-CA19-9 (190.30).

The following Local Coverage Determination (LCD) is located at fcso.com: Molecular Pathology Procedures (L34519).

The following Billing and Coding Article is located at fcso.com: Billing and Coding: Molecular Pathology and Genetic Testing (A58918).

The following decision memo is located at cms.gov and was reviewed on the last guideline reviewed date: Decision Memo for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (CAG-00450N).

The following are located at cms.gov: Molecular Diagnostic Services (MoIDX) coverage determinations.

## DEFINITIONS:

**A2-PAG:** pregnancy-associated alpha-2 glycoprotein (a chemical made by some cancers, consisting of a combination of protein and sugars).

**BCM:** breast cancer mucin; a marker made by some breast cancers.

**CAM17-1, CAM26, CAM29:** also known as monoclonal anti-mucin antibody markers, are markers noted in certain cancers.

**CAR-3:** a marker that reacts with a special test using a specific protein testing substance called “monoclonal antibody AR-3”.

**Carbohydrate cancer antigens:** CA 19-9, CA-125, CA 15-3/CA27-23, CA 242, CA 50, CA 72-4, CA 195, CA 549, M26, M29: these and other markers are a way to test for special markers on tumors, that are made of carbohydrates (a chemical that resembles a type of sugar).

**CgA:** a major protein of the granin family that has been described as a potential marker for neuroendocrine tumors.

**CellSearch®:** a serum-based test that measures circulating tumor cells.

**DU-PAN-2:** a chemical (sialylated carbohydrate antigen) that may be found with some cancers.

**FibroSpect II:** serum marker panels for the diagnosis or clinical management of liver disease.

**FibroSure:** serum marker panels for the diagnosis or clinical management of liver disease.

**GeneSearch BLN:** an assay for the detection of greater than 0.2mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients.

**HE4:** an enzyme immunoassay for the quantitative determination of Human Epididymis Protein 4 (HE4) antigen in ovarian cancer.

**LPA:** lysophosphatidic acid; a chemical that has been suggested as a possible test for ovarian cancer, body levels may be high in other cancers as well.

**MCA:** a chemical (Mucin-like Carcinoma-associated Antigen) that may be found in breast cancers.

**MSA:** a chemical (Mammary Serum Antigen) that may be found in breast cancers.

**NSE:** Neuron-Specific Enolase, a chemical made in the presence of some cancers.

**Ova Check™:** a serum-based test for the early detection of epithelial ovarian cancer.

**OvaSure™:** ovarian cancer-screening test that may be able to assess the presence of early stage ovarian cancer in high-risk woman.

**Pathwork Tissue of Origin:** a diagnostic test that may aid in the diagnosis of tumors with uncertain origins.

**P-LAP:** placental alkaline phosphatase, a chemical made in the presence of some cancers.

**PNA/ELLA:** peanut lectin bonding assay, a test for a certain tumor marker.

**Proteogenomic Testing:** involves the integration of proteomic, transcriptomic, and genomic information.

**Proteomic Testing:** the measurement of protein products *alone*, without integration of genomic and transcriptomic information.

**SLEX, SLX:** sialylated Lewis X-I antigen and sialylated SSEA-1 antigen.

**SPAN-1:** a sialylated carbohydrate antigen.

**ST-439:** a sialylated carbohydrate antigen.

**TAG12, TAG 72, TAG 72.3:** tumor associated glycoproteins; chemicals made by some cancers, consisting of a combination of protein and sugars.

**TATI:** tumor-associated trypsin inhibitor, a chemical made by the body, in the presence of some cancers.

**TNF-a:** tumor necrosis factor alpha, a chemical made by the immune system in the presence of some cancers.

**TPA:** tissue polypeptide antigen is a marker that may be present on some cancers.

## **RELATED GUIDELINES:**

[Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer, 05-86000-26](#)

[Genetic Testing, 05-82000-28](#)

[Molecular Testing for the Management of Pancreatic Cysts, Barrett Esophagus, and Solid Pancreatic Lesions, 05-86000-27](#)

[Somatic Biomarker Testing \(KRAS, NRAS, BRAF, HER2\), Including Liquid Biopsy and MicroRNA Expression Testing, in Metastatic Colorectal Cancer, 05-86000-28](#)

## OTHER:

None applicable.

## REFERENCES:

1. Akerley WL, et al, The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer, *Curr Med Res Opin.* 2013 May;29(5):517-25.
2. Alexander EK, Schorr M, Klopper J, et al. Multicenter clinical experience with the Afirma gene expression classifier. *J Clin Endocrinol Metab.* Jan 2014;99(1):119-125.
3. American Academy of Dermatology. Clinical Guidelines; accessed at [aad.org](http://aad.org).
4. American Academy of Ophthalmology, Preferred Practice Pattern: Dry Eye Syndrome, 2013. Accessed at [aao.org](http://aao.org) 09/22/16.
5. American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA). Recommendations for Testing, Managing, and Treating Hepatitis C. 2016; accessed at [hcvguidelines.org](http://hcvguidelines.org).
6. American College of Obstetricians and Gynecologists, Committee Opinion Number 477- The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer, March 2011.
7. American Society of Clinical Oncology (ASCO). Clinical Guidelines; accessed at [asco.org](http://asco.org).
8. American Society of Clinical Oncology (ASCO) Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small Cell Lung Cancer Considering First-Line EGFR Tyrosine-Kinase Inhibitor (TKI) Therapy, 2011. Accessed at [asco.org](http://asco.org) 04/02/13.
9. Arnot SP, Han G, et al. Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy. *Am J Surg.* 2021 Jun;221(6):1195-1199. PMID:33773750.
10. Berman B, Ceiley R, et al. Appropriate Use Criteria for the Integration of Diagnostic and Prognostic Gene Expression Profile Assays into the Management of Cutaneous Malignant Melanoma: An Expert Panel Consensus-Based Modified Delphi Process Assessment. *SKIN.* 2019; 3(5):291-298.
11. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.07 Urinary Biomarkers for Cancer Screening, Diagnosis, and Surveillance, 01/24.
12. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.14, Evaluation of Biomarkers for Alzheimer Disease, 07/23.
13. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.19 Pharmacogenomic and Metabolite Markers for Patients Treated With Thiopurines, 12/23.
14. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.41 Noninvasive Techniques for the Evaluation and Monitoring of Patients with Chronic Liver Disease, 12/23.
15. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.45 Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Non-Small-Cell Lung Cancer (EGFR, ALK, BRAF, ROS1, RET, MET, KRAS, HER2, PD-L1, TMB); 12/23.

16. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.54 Gene Expression–Based Assays for Cancers of Unknown Primary, 04/23.
17. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.62, Multimarker Serum Testing Related to Ovarian Cancer, 01/24.
18. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.66 Serum Biomarker Human Epididymis Protein 4, 01/24.
19. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.78 Molecular Markers in Fine Needle Aspirates of the Thyroid, 09/23.
20. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.84 Measurement of Serum Antibodies to Selected Biologic Agents, 12/23.
21. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.97 Microarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification, 11/23.
22. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.100, Cardiovascular Risk Panels, 01/24.
23. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.119 Multibiomarker Disease Activity Blood Test for Rheumatoid Arthritis, 07/23.
24. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.120, Gene Expression Profiling for Uveal Melanoma, 03/23.
25. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.121, Miscellaneous Genetic and Molecular Diagnostic Tests, 09/23.
26. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.123, Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases, 07/23.
27. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.125 Proteomic Testing for Targeted Therapy in Non-Small-Cell Lung Cancer, 12/23.
28. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.140, Proteogenomic Testing for Patients With Cancer, 07/23.
29. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup> 2.04.142, Molecular Testing in the Management of Pulmonary Nodules, 06/23.
30. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.146 Gene Expression Profiling for Cutaneous Melanoma, 06/23.
31. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.150 Serologic Genetic and Molecular Screening for Colorectal Cancer, 08/23.
32. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>; 2.04.153 Tumor-Informed Circulating Tumor DNA Testing for Cancer Management, 10/23.
33. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>; 2.04.158 Multicancer Early Detection Testing, 07/23.
34. Boac BM, Xiong Y, et al. Adherence to practice guidelines is associated with reduced referral times for patients with ovarian cancer. *Am J Obstet Gynecol.* 2018 Apr;218(4):436.e1-436.e7.

35. Brodsky BS, Owens GM, et al, Economic Impact of Increased Utilization of Multivariate Assay Testing to Guide the Treatment of Ovarian Cancer: Implications for Payers, AHDB October 2017 Vol 10, No 7.
36. Buzaid AC, Gershenwals JE. Tumor, node, metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma. In: UpToDate, Atkins MB, Shah S (Eds), UpToDate, Waltham, MA; accessed May 2023 at uptodate.com.
37. Carbone et al, Clinical Validity: BR21 – Prognostic Effect of VeriStrat, Journal of Thoracic Oncology, 2012.
38. Castle Biosciences, Inc. DecisionDx<sup>®</sup>-Melanoma Clinical Dossier, 2022.
39. Castle Biosciences, Inc. myPath<sup>®</sup> Melanoma Clinical Dossier, 2022.
40. Castle Biosciences, Inc. myPath<sup>®</sup> Melanoma Technology Updates, 2022.
41. Centers for Medicare & Medicaid Services (CMS), Decision Memo for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (CAG-00450N); accessed at cms.gov.
42. Centers for Medicare & Medicaid Services (CMS). Molecular Diagnostic Services (MOLDX) Coverage Determinations, accessed at cms.gov.
43. Centers for Medicare & Medicaid Services (CMS), NCD for Tumor Antigen by Immunoassay- CA 125 (190.28), accessed at cms.gov.
44. Centers for Medicare & Medicaid Services (CMS), NCD for Tumor Antigen by Immunoassay- CA 15-3/CA 27.29 (190.29), accessed at cms.gov.
45. Centers for Medicare & Medicaid Services (CMS), NCD for Tumor Antigen by Immunoassay – CA19-9 (190.30), accessed at cms.gov.
46. Chakravarty D, Johnson A, et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol. 2022 Apr 10;40(11):1231-1258.
47. Chan, D.W., Beveridge, R.A., Muss, H., et al., Use of Truquant BR Radioimmunoassay for Early Detection of Breast Cancer Recurrence in Patients with Stage II and Stage III Disease. Journal of Clinical Oncology. 1997; Vol. 15(6): 2322-2328.
48. Chan L, Nadkarni GN, et al. Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease. Diabetologia. 2021 Jul;64(7):1504-1515.
49. Chu QS. Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion. Ther Adv Med Oncol. 2020 Jan 23;12:1758835919895756.
50. Cibas ES, Ali SZ, The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017 Nov;27(11):1341-1346.
51. Cibas ES, Baloch ZW, et al, A prospective assessment defining the limitations of thyroid nodule pathologic evaluation; Ann Intern Med. 2013 Sep 3;159(5):325-32.
52. Clark TA, Chung JH, et al. Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA. J Mol Diagn. 2018 Sep;20(5):686-702.

53. Clarke LE, Pimentel JD, et al. Gene expression signature as an ancillary method in the diagnosis of desmoplastic melanoma. *Hum Pathol.* 2017 Dec;70:113-120.
54. Cockerell C, Ceilley R, et al. Using Genomics to Improve Pigmented Lesion Management & Health Outcomes. *SKIN The Journal of Cutaneous Medicine*, 6(2), 87–89. 2022; <https://doi.org/10.25251/skin.6.2.1>.
55. Cockerell CJ, Tschen J, et al. The influence of a gene expression signature on the diagnosis and recommended treatment of melanocytic tumors by dermatopathologists. *Medicine (Baltimore)*. 2016 Oct;95(40):e4887.
56. Cockerell C, Tschen J, et al. The influence of a gene-expression signature on the treatment of diagnostically challenging melanocytic lesions. *Per Med.* 2017 Mar;14(2):123-130.
57. Committee on Gynecologic Practice, Society of Gynecologic Oncology. Committee Opinion No. 716: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk. *Obstet Gynecol.* 2017 Sep;130(3):e146-e149.
58. Curtis JR, van der Helm-van Mil AH, Knevel R et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. *Arthritis Care Res (Hoboken)* 2012; 64(12): 1794-1803.
59. DermTech Inc. Pigmented Lesion Assay (PLA) Clinical Supporting Document, April 2022.
60. Diggans J, Kim SY, Hu Z, et al. Machine learning from concept to clinic: reliable detection of braf v600e DNA mutations in thyroid nodules using high-dimensional RNA expression data. *Pac Symp Biocomput.* 2015;20:371-382.
61. Doroshow JH, Selecting Systemic Cancer Therapy One Patient at a Time: Is There a Role for Molecular Profiling of Individual Patients With Advanced Solid Tumors? *Journal of Clinical Oncology*, Vol 28, 2010.
62. Dingli D, Ailawadhi S, Bergsagel PL, et al. Therapy for relapsed multiple myeloma: Guidelines from the Mayo Stratification for Myeloma and Risk-Adapted Therapy. *Mayo Clin Proc.* Apr 2017;92(4):578-598.
63. Duchnowska R, et al, Correlation Between Quantitative HER2 Protein Level and the Risk of Brain Metastasis in Patients with Metastatic Breast Cancer Treated with Trastuzumab-Containing Therapy, *J Clin Oncol*, 28:15s, 2010 (suppl; abstr 1030).
64. Dunton Cj, Bullock RG, Fritsche H. Ethnic disparity in clinical performance between multivariate index assay and CA125 in detection of ovarian malignancy. *Future Oncol.* 2019 Sep;15(26):3047-3051.
65. Dunton CJ, Eskander RN, et al. Low-risk multivariate index assay scores, physician referral and surgical choices in women with adnexal masses. *Curr Med Res Opin.* 2020 Dec;36(12):2079-2083.
66. Dunton CJ, Hutchcraft ML, et al. Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative. *Diagnostics* 2021, 11, 1440.
67. Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P et al. Lipid-related markers and cardiovascular disease prediction. *JAMA* 2012; 307(23):2499-506.
68. Eskander RN, Carpenter BA, et al. The clinical utility of an elevated-risk multivariate index assay score in ovarian cancer patients. *Curr Med Res Opin.* 2016 Jun;32(6):1161-5.
69. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program Expert Panel

- on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III). *JAMA* 2001;285:2486-2497.
70. Fakhri M, Sandhu J, et al. Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer. *JAMA Netw Open*. 2022 Mar 1;5(3):e221093. PMID: 35258578.
  71. Farberg AS, Marson JW, et al. Expert Consensus on the Use of Prognostic Gene Expression Profiling Tests for the Management of Cutaneous Melanoma: Consensus from the Skin Cancer Prevention Working Group. *Dermatol Ther (Heidelb)*. 2022 Apr;12(4):807-823.
  72. Ferraro S, Robbiano C, et al. Serum human epididymis protein 4 vs. carbohydrate antigen 125 in ovarian cancer follow-up. *Clin Biochem*. 2018 Sep;60:84-90. Doi: 10.1016/j.clinbiochem.2018.08.003. Epub 2018 Aug 18. PMID: 30125544.
  73. First Coast Service Options, Inc. (FCSO). Billing and Coding Article: Billing and Coding: Molecular Pathology and Genetic Testing (A58918); accessed at fcso.com.
  74. First Coast Service Options, Inc. (FCSO). Local Coverage Determination (LCD) Molecular Pathology Procedures (L34519); accessed at fcso.com.
  75. Foulks GN, Forstot SL, et al. Clinical guidelines for management of dry eye associated with Sjogren disease. *Ocul Surf*. 2015;13(2):118-132.
  76. Freudenberg JA, Bembas K, Greene MI, Zhang H, Non-Invasive, Ultra-Sensitive, High-Throughput Assays to Quantify Rare Biomarkers in the Blood, *Methods*, 2008 Jun 20.
  77. Fried L, Tan A, et al. Technological advances for the detection of melanoma: Advances in molecular techniques. *J Am Acad Dermatol*. 2020 Oct;83(4):996-1004. PMID: 32360759.
  78. Fung MA, Vidal CI, et al. Appropriate use criteria for ancillary diagnostic testing in dermatopathology: New recommendations for 11 tests and 220 clinical scenarios from the American Society of Dermatopathology Appropriate Use Criteria Committee. *J Cutan Pathol*. 2022 Mar;49(3):231-245.
  79. Genomic Health, Inc. OncoExTra™ Assay Dossier; 03/23.
  80. Goodrich ST, Bristow RE, et al. The effect of ovarian imaging on the clinical interpretation of a multivariate index assay. *Am J Obstet Gynecol*. 2014 Jul;211(1):65.e1-65.e11.
  81. Gregorc et al, Predictive Value of a Proteomic Signature in Patients with Non-Small-Cell Lung Cancer Treated with Second-Line Erlotinib or Chemotherapy (PROSE): A Biomarker-Stratified, Randomised Phase 3 Trial, *The Lancet Oncology*, 2014.
  82. Greenhaw BN, Covington KR, et al. Molecular Risk Prediction in Cutaneous Melanoma: A Meta-Analysis of the 31-gene Expression Profile Prognostic Test in 1,479 Patients. *J Am Acad Dermatol*. 2020 Mar 27;S0190-9622(20)30475-8.
  83. Greenland P, Alpert JS, Beller GA et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2010; 56(25):e50-103.
  84. Grossman D, Okwundu N, et al. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. *JAMA Dermatol*. 2020 Sep 1;156(9):1004-1011. PMID: 32725204.

85. Guardant Health Dossier: Use of the Guardant360® Cell-free Circulating Tumor DNA Test in Advanced Non-Small Cell Lung Cancer, 09/12/17.
86. Gyawali B, West HJ. Plasma vs Tissue Next-Generation Sequencing in Non-Small Cell Lung Cancer- Either, Both, or Neither? *JAMA Oncol.* 2019 Feb 1;5(2):148-149. doi:10.1001/jamaoncol.2018.4304
87. Hambardzumayan K et al. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. *Annals of Rheum Dis* doi:10.1136/annrheumdis-2013-204986.
88. Harrell RM, Bimston DN, Surgical utility of Afirma: effects of high cancer prevalence and oncocyctic cell types in patients with indeterminate thyroid cytology; *Endocr Pract.* 2014 Apr;20(4):364-9.
89. Haugen BR, Alexander EK, Bible KC, et al. American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid.* Jan 2016;26(1):1-133.
90. Havrilesky L, Whitehead C, Rubatt J, et al, Evaluation of Biomarker Panels for Early Stage Ovarian Cancer Detection and Monitoring for Disease Recurrence, *Gynecol Oncol*, 2008 Jun 25.
91. Henriksen TV, Tarazona N, et al. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences. *Clin Cancer Res.* 2022 Feb 1;28(3):507-517.
92. Hirata S et al. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. *Rheumatology (Oxford)* 2013;52:1202-07.
93. Hornberger et al, Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: Extended analysis of the PROSE trial, *Lung Cancer*, 2015.
94. Hsueh EC, DeBloom JR, et al. Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma. *JCO Precis Oncol.* 2021 Apr 6;5:PO.20.00119.
95. Hyams DM, Covington KR, et al. Integrating the melanoma 31-gene expression profile test with surgical oncology practice within national guideline and staging recommendations. *Future Oncol.* Feb 2021; 17(5):517-527. PMID 33021104.
96. James NE, Chhester C, Ribeiro JR. Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian Cancer. *Front Oncol.* 2018 Apr 24;8:124.
97. Janas L. Current clinical application of serum biomarkers to detect and monitor ovarian cancer – update. *Prz Menopauzalny.* 2021 Dec;20(4):211-216.
98. Jamshidi A, Liu MC, et al. Evaluation of cell-free DNA approaches for multi-cancer early detection. *Cancer Cell.* 2022 Dec 12;40(12):1537-1549.e12. doi: 10.1016/j.ccell.2022.10.022. PMID: 36400018.
99. Kangas-Dick AW, Greenbaum A, et al. Evaluation of a Gene Expression Profiling Assay in Primary Cutaneous Melanoma. *Ann Surg Oncol.* 2021 Jan 23. PMID:33486642.
100. Kashani-Sabet M, Leachman SA, et al. Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing. *JAMA Dermatol.* 2023 Mar 15. Doi: 10.1001/jamadermatol.2023.0127. PMID: 36920356.



101. Kasi PM, Chakrabarti S, et al. BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours. *BMJ Open*. 2022 May 30;12(5):e060342. PMID:35636789.
102. Ko JS, Clarke LE, et al. Correlation of melanoma gene expression score with clinical outcomes on a series of melanocytic lesions. *Hum Pathol*. 2019 Apr;86:213-221.
103. Ko JS, Matharoo-Ball B, et al. Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes. *Cancer Epidemiol Biomarkers Prev*. 2017 Jul;26(7):1107-1113.
104. Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. *Am J Gastroenterol*. 2010 Mar;105(3):501-23; accessed at [gi.org/clinical-guidelines](http://gi.org/clinical-guidelines) 07/31/13.
105. Lam D, Nadkarni GN, et al. Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial. *Am J Nephrol*. 2022;53(1):21-31.
106. Lastra RR, Pramick MR, Crammer CJ, et al. Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: an institutional experience. *Cancer Cytopathol*. Oct 2014;122(10):737-744.
107. Lawton FB, Pavlik EJ. Perspectives on Ovarian Cancer 1809 to 2022 and Beyond. *Diagnostics (Basel)*. 2022 Mar 24;12(4):791.
108. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: management of Crohn's disease in adults. *Am J Gastroenterol*. Apr 2018;113(4):481-517.
109. Litchman GH, Prado G, et al. A Systematic Review and Meta-Analysis of Gene Expression Profiling for Primary Cutaneous Melanoma Prognosis. *SKIN J Cutaneous Med* 2020;4:221-37.
110. Liu V, Armstrong AW. Pathologic characteristics of melanoma. In: UpToDate, Atkins MB, Tsao H, corona R (Eds), UpToDate, Waltham, MA; accessed May 2023 at [uptodate.com](http://uptodate.com).
111. Longoria TC, Ueland FR, et al. Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer. *Am J Obstet Gynecol*. 2014 Jan;210(1):78.e1-9.
112. Loupakis F, Sharma S, et al. Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases. *JCO Precis Oncol*. 2021 Jul 21;5:PO.21.00101. PMID:34327297.
113. Lowrance WT, Scardino PT, Predictive Models for Newly Diagnosed Prostate Cancer Patients, *Rev Urol*. 2009 Summer; 11(3): 117-126.
114. Magbanua MJM, Swigart LB, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. *Ann Oncol*. 2021 Feb;32(2):229-239. PMID:33232761. Marchetti MA, Coit DG, et al. Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma: A Systematic Review and Meta-analysis. *JAMA Dermatol*. 2020 Sep 1;156(9):953-962. PMID:32745161.
115. Matsusaka S, Mizunuma N, Terui Y, et al, Use of Circulating Tumor Cells and Circulating Endothelial Cells as Surrogate Markers for FOLFOX4 With or Without Bevacizumab in mCRC, American Society of Clinical Oncology, 2009 Gastrointestinal Cancers Symposium.

116. McIver B, Castro MR, Morris JC, et al. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules. *J Clin Endocrinol Metab.* Nov 2014;99(11):4069-4077.
117. Mack PC, Banks KC, et al. Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases. *Cancer.* 2020 Jul 15;126(14):3219-3228.
118. Medeiros F, Kolbert CP, Rohakhtar R, et al, A Gene Expression Microarray-Based Diagnostic Test Applied to Patients with Carcinoma of Unknown Primary, *J Clin Oncol* 26: 2008, May 20 suppl.
119. Miller RW, et al, Performance of the American College of Obstetricians and Gynecologists' Ovarian Tumor Referral Guidelines with a Multivariate Index Assay, *Obstetrics & Gynecology*, Vol. 117, NO. 6, June 2011.
120. Minasian LM, Pinsky P, et al. Study design considerations for trials to evaluate multicancer early detection assays for clinical utility. *J Natl Cancer Inst.* 2023 Mar 9;115(3):250-257. PMID:36458902.
121. Monzon FA, Henner WD, Medeiros F, Use of a Microarray-Based 1550-Gene Expression Profile in the Diagnosis of Carcinoma of Unknown Primary (CUP), American Society of Clinical Oncology, 2009 Gastrointestinal Cancers Symposium.
122. Monzon FA, Lyons-Weiler M, Buturovic LJ, et al, Multicenter Validation of a 1,550 Gene Expression Profile for Identification of Tumor Tissue of Origin, *J Clin Oncol*, Vol 27, No 15, May 2009.
123. Moore RG, Brown AK, Miller CM, Badgwell, et al, Utility of a Novel Serum Tumor Biomarker HE4 in Patients with Uterine Cancer, *Journal of Clinical Oncology*, 2008 May 19.
124. Nadkarni GN, Takale D, et al. A Post Hoc Analysis of KidneyIntelX and Cardiorenal Outcomes in Diabetic Kidney Disease. *Kidney360.* 2022 May 18;3(9):1599-1602.
125. Natera™ Signatera™ Residual Disease Test (MRD) Dossier, 03/22.
126. National Comprehensive Cancer Network (NCCN), Clinical Practice Guidelines in Oncology; located at [nccn.org](http://nccn.org).
127. National Institute for Health and Care Excellence (NICE). Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel. 2013; accessed at [nice.org.uk/guidance](http://nice.org.uk/guidance) 12/17/18. Ordas I, Mould DR, Feagan BG et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. *Clin Pharmacol Ther* 2012; 91(4):635-46.
128. Owens L, Gulati R, Etzioni R. Stage Shift as an Endpoint in Cancer Screening Trials: Implications for Evaluating Multicancer Early Detection Tests. *Cancer Epidemiol Biomarkers Prev.* 2022 Jul 1;31(7):1298-1304.
129. Pal SK, Agarwal N, Boorjian SA, et al. National Comprehensive Cancer Network recommendations on molecular profiling of advanced bladder cancer. *J Clin Oncol.* Sep 20 2016;34(27):3346-3348.
130. Palmetto GBA, MolDX LCDs located at [palmettogba.com](http://palmettogba.com).
131. Piotrowska Z, Drapkin B, et al, Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR-Mutant Lung Cancer. *J Thorac Oncol.* 2016 Aug;11(8):e95-7. Doi: 10.1016/j.jtho.2016.03.020.
132. Pons-Belda OD, Fernandez-Uriarte A, Diamandis EP. Multi Cancer Early Detection by Using Circulating Tumor DNA-The Galleri Test. Reply to Klein et al. The Promise of Multicancer Early Detection. Comment on "Pons-Belda et al. Can Circulating Tumor DNA Support a Successful

- Screening Test for Early Cancer Detection? The Grail Paradigm. *Diagnostics* 2021, 11, 2171". *Diagnostics* (Basel). 2022 May 17;12(5):1244. doi: 10.3390/diagnostics12051244.
133. Powles T, Assaf ZJ, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. *Nature*. 2021 Jul;595(7867):432-437. PMID:34135506.
  134. Qu KZ, Li H, Whitmire R, Sferruzza A, Bender RA, Human Epididymis Secretory Protein 4 in Serum (HE4) as a Marker of Ovarian Cancer, *J Clin Oncol* 26: 2008, May 20 suppl.
  135. Raghav K, Morris V, et al, MET amplification in metastatic colorectal cancer: An acquired response to EGFR inhibition, not a de novo phenomenon. *Oncotarget*. 2016 Jul 13. Doi: 10.18632/oncotarget.10559.
  136. Rauniyar N, Peng G, et al, Data-Independent Acquisition and Parallel Reaction Monitoring Mass Spectrometry Identification of Serum Biomarkers for Ovarian Cancer; *Biomark Insights*. 2017 Jun 5;12:1177271917710948.
  137. Reilly GP, Dunton CJ, et al. Validation of a deep neural network-based algorithm supporting clinical management of adnexal mass. *Front Med (Lausanne)*. 2023 Jan 23;10:1102437.
  138. Ross JS, et al, The Her-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine, *The Oncologist* 2009; 14: 320-368.
  139. Santos ES, Raez LE, et al; Genomic Tissue Analysis and Liquid Biopsy Profiles from Patients Diagnosed with Advanced Adenocarcinoma of the Lung. *Clin Oncol*. 2016; 1: 1099.
  140. Schrock AB, Welsh A, et al. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer. *J Thorac Oncol*. 2019 Feb;14(2):255-264. Doi: 10.1016/j.jtho.2018.10.008. Epub 2018 Oct 24. PMID: 30368012.
  141. Schwaederle M, Husain H, et al, Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. *Oncotarget*. 2016 Mar 1;7(9):9707-17. Doi: 10.18632/oncotarget.7110.
  142. Singer J, Hanna JW, et al, Impact of a gene expression classifier on the long-term management of patients with cytologically indeterminate thyroid nodules. *Curr Med Res Opin*. 2016 Jul;32(7):1225-32.
  143. Skelsey M, Brouha B, et al. Non-Invasive Detection of Genomic Atypia Increases Real-World NPV and PPV of the Melanoma Diagnostic Pathway and Reduces Biopsy Burden. 2021 *SKIN The Journal of Cutaneous Medicine*, 5(5), 512–523.
  144. Skudalski L, Waldman R, et al. Melanoma: How and when to consider clinical diagnostic technologies. *J Am Acad Dermatol*. 2022 Mar;86(3):503-512. PMID: 34915058.
  145. Society of Gynecologic Oncologists, Statement Regarding OVA1, 09/09, accessed at sgo.org.
  146. Society of Gynecologic Oncologists, Statement Regarding OvaCheck™, 07/08, accessed at sgo.org.
  147. Society of Gynecologic Oncologists, Statement Regarding OvaSure™, 07/08, accessed at sgo.org.
  148. Spitzer G, Socinski MA. Alternative Strategy to Achieve Increased Overall Survival and Better Quality of Life in Patients With Second-Line Advanced Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2015;33(5):522-523.
  149. Steward DL, Kloos RT, Clinical Diagnostic Gene Expression Thyroid Testing; *Otolaryngol Clin North Am*. 2014 Aug;47(4):573-93.

150. Stinchcombe et al, Clinical Validity Data: Phase II Blinded Study, *Journal of Thoracic Oncology*, 2013.
151. Swetter S, Geller AC. Melanoma: Clinical features and diagnosis. In: UpToDate, Tsao H, Corona R (Eds), UpToDate, Waltham, MA; accessed at [uptodate.com](http://uptodate.com).
152. Swetter SM, Tsao H, et al. Guidelines of care for the management of primary cutaneous melanoma. *J Am Acad Dermatol*. 2019 Jan;80(1):208-250; accessed at [jaad.org](http://jaad.org).
153. Sullivan PS, Hirschowitz SL, et al, The impact of atypia/follicular lesion of undetermined significance and repeat fine-needle aspiration: 5 years before and after implementation of the Bethesda System; *Cancer Cytopathol*. 2014 Dec;122(12):866-72.
154. Taguchi et al, Development and Initial Validation of VeriStrat, *Journal of the National Cancer Institute*, 2007.
155. Tanaka F, Hashimoto M, Takuwa T, et al, Circulating Tumor Cells (CTCs) and endothelial Cells (CECs) in Malignant Pleural Mesothelioma (MPM) and Primary Lung Cancer, *J Clin Oncol* 26: 2008 May 20 suppl.
156. Tang WHW, Yimer H, et al. Performance of a targeted methylation-based multi-cancer early detection test by race and ethnicity. *Prev Med*. 2023 Feb;167:107384. PMID: 36495927.
157. Thompson JC, Yee SS, et al; Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. *Clin Cancer Res*. 2016 Sep 6.
158. Tie J, Cohen JD, et al. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. *N Engl J Med*. 2022 Jun 16;386(24):2261-2272.
159. Tokita J, Vega A, et al. Real World Evidence and Clinical Utility of KidneyIntelX on Patients With Early-Stage Diabetic Kidney Disease: Interim Results on Decision Impact and Outcomes. *J Prim Care Community Health*. 2022 Jan-Dec;13:21501319221138196.
160. Tran MC, Strohbehm GW, et al. Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression. *Clin Lung Cancer*. 2023 May;24(3):e117-e121.
161. Tschen J, Davies P, et al. Clinical Use of a Diagnostic Gene Expression Signature for Melanocytic Neoplasms. *Cutis*. 2021 May;107(5):264-269.
162. Ueland FR. Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, fallopian tube, or peritoneum. In: UpToDate, Goff B, Chakrabarti A (Eds), UpToDate, Waltham, MA; accessed at [uptodate.com](http://uptodate.com).
163. Ueland FR, A Perspective on Ovarian Cancer Biomarkers: Past, Present and Yet-To-Come; *Diagnostics (Basel)*. 2017 Mar; 7(1): 14.
164. Ueland FR, Desimone CP, et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. *Obstet Gynecol*. 2011 Jun;117(6):1289-97.
165. U.S. Food and Drug Administration (FDA); accessed at [fda.gov](http://fda.gov).
166. U.S Preventive Services Task Force (USPSTF), USPSTF Recommendations, accessed at: [uspreventiveservicestaskforce.org](http://uspreventiveservicestaskforce.org).
167. Urban RR, Smith A, et al. Evaluation of a Validated Biomarker Test in Combination With a Symptom Index to Predict Ovarian Malignancy. *Int J Gynecol Cancer*. 2017 Feb;27(2):233-238.

168. Vermillion Inc. Dossier: The Clinical and Economic Value of OVA1/MIA, 04/20/17.
169. Vermillion Inc. Presentation: OVA1<sup>®</sup> Testing and Optimal Management of the Adnexal Mass. April 2019.
170. Vetto JT, Hsueh EC, et al. Guidance of Sentinel Lymph Node Biopsy Decisions in Patients With T1-T2 Melanoma Using Gene Expression Profiling. *Future Oncol.* 2019 Apr;15(11):1207-1217.
171. Viera AJ. Overview of preventive care in adults – UpToDate. Elmore JG, Givens J, Swenson S (Eds.); accessed June 2023 at uptodate.com.
172. Villaflor V, Won B, et al, Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. *Oncotarget.* 2016 Sep 1. Doi: 10.18632/oncotarget.11801.
173. Visintin I, Feng Z, Longton G, Ward D, et al, Diagnostic Markers for Early Detection of Ovarian Cancer, *Clinical Cancer Research* 14, 1065-1072, February 15, 2008.
174. Wang SL, Hauenstein S, et al, Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay, *Journal of Pharmaceutical and Biomedical Analysis* 78– 79 (2013) 39– 44.
175. White T, Szelinger S, et al. Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra<sup>®</sup>, *Oncotarget.* 2021 Apr 13;12(8):726-739. Doi: 10.18632/oncotarget.27945.
176. Wu J, Yan F, Zhang X, et al, Disposable Reagentless Electrochemical Immunosensor Array Based on a Biopolymer/Sol-Gel Membrane for Simultaneous Measurement of Several Tumor Markers, *Clinical Chemistry*, June 2008.
177. Zhang S, Brazel D, et al. Utility of tumor-informed circulating tumor DNA in the clinical management of gastrointestinal malignancies. *J Gastrointest Oncol.* 2021 Dec;12(6):2643-2652. PMID:35070394.
178. Zhou C, Yuan X, et al. Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors. *J Hematol Oncol.* 2018 Nov 6;11(1):129.
179. Ziyambe B, Yahya A, et al. A Deep Learning Framework for the Prediction and Diagnosis of Ovarian Cancer in Pre- and Post-Menopausal Women. *Diagnostics (Basel).* 2023 May 11;13(10):1703.
180. Zubek VB, Konski A, Cost Effectiveness of Risk-Prediction Tools in Selecting Patients for Immediate Post-Prostatectomy Treatment, *Molecular Diagnosis & Therapy*, Volume 13, Number 1, 2009, pp. 31-47.

### COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Medical Policy and Coverage Committee on 12/08/23.

### GUIDELINE UPDATE INFORMATION:

02/15/04	Developed separate guideline for non-covered tumor markers from the Tumor Markers guideline. Added program exception and added diagnoses [155.1, 156.1, 156.8, 156.9, 157.0 – 157.9, 197.8, 235.3, 235.5, V10.09] for 86301 for Medicare & More.
----------	--

02/15/05	Deleted CA 19-9 from the investigational statement. Deleted Medicare program exception. Deleted the following from the when services are covered section of the MCG (per MPCC recommendation): Non-covered/investigational serum tumor markers may be covered if the individual subscriber has a benefit to cover non-covered/investigational services (refer to contract benefits). Updated related guidelines section.
08/15/07	Review, investigational status maintained, guideline reformatted, references updated.
09/15/08	Annual review: Position statements maintained. Description section and references updated.
08/15/09	Annual review: Guideline title changed, position statements updated, position statements from other tumor marker guidelines incorporated, description section, coding and references updated.
12/15/09	Updated the list of experimental/investigational tests.
01/01/10	Annual HCPCS coding update: added code 86305.
04/15/10	Updated the list of experimental/investigational tests and the Medicare Advantage program exception.
11/15/10	Revision; updated the list of experimental/investigational tests and added related ICD-10 codes.
08/15/11	Revision; Medicare Advantage and references updated; formatting changes.
01/01/12	Annual HCPCS update. Added CPT codes 0279T, 0280T.
04/01/12	Quarterly HCPCS update. Deleted HCPCS code S3711.
08/24/12	Reimbursement section updated.
10/15/12	Serum Antibodies for the Diagnosis of Inflammatory Bowel Disease position statement removed and added to the Genetic Testing guideline; reimbursement section updated.
11/15/12	List of experimental/investigational tests updated.
01/01/13	Annual HCPCS update. Added codes 81500, 81503, 81506, 86152, 86153, 0001M-0003M; deleted codes 0279T & 0280T. Updated position statement section and references.
02/15/13	Revision; position statement section and references updated.
03/15/13	Revision; position statement section including the list of investigational tests and references updated; title change.
05/15/13	Revision; position statement, billing/coding, program exception, and reference sections updated.
09/15/13	Revision; position statement section and references updated.
01/01/14	Annual HCPCS update. Added code 81504.
02/15/14	Revision; position statement section, Medicare program exception, and references updated.
06/15/14	Revision; position statement section, Coding, Medicare program exception, and references updated.
07/01/14	Quarterly HCPCS update. Added code 0007M.
10/15/14	Revision; Update the position statement and coding sections, program exception, and references.
01/01/15	Annual HCPCS/CPT update. Added codes 87505-87507.
06/15/15	Revision; position statement section, billing/coding, and references updated.
11/01/15	Revision: ICD-9 Codes deleted.

11/15/15	Revision; program exception and references updated.
01/01/16	Annual HCPCS/CPT update; codes 81490, 81538, 81540, 81545 added, code 0103T deleted.
03/15/16	Revision; position statement section, coding and references updated.
09/15/16	Revision; position statement section, program exception, and references updated.
11/15/16	Revision; position statement section and references updated.
12/15/16	Revision; position statement, coding, and references updated.
02/01/17	Coding Update; new code 0003U added; investigational test list updated.
02/15/17	Revision; position statements, coding, and references updated.
03/15/17	Revision; Multianalyte assays for chronic liver disease position statements revised; coding and references updated.
04/15/17	Revision; Uveal Melanoma position statement added and references updated.
06/15/17	Revision; test names added to Biochemical Markers of Alzheimer's Disease & Circulating Tumor DNA position statements section; investigational test list updated.
07/15/17	Revision; Investigational test list updated.
08/01/17	Coding update; Added code 0009U.
12/15/17	Revision; Position statement section updated including the addition of ROS1 coverage statement; program exception and references updated.
01/01/18	Annual CPT/HCPCS update. Added code 0026U.
02/15/18	Revision; Circulating tumor DNA position statement added; OVA1, Overa, and ROMA tests position statement added and references updated.
04/01/18	Quarterly HCPCS/CPT update. Added codes 0012M and 0013M.
05/15/18	Revision; position statements, coding, and references updated.
09/15/18	Revision; position statements and references updated.
10/01/18	Quarterly HCPCS/CPT update. Added code 0062U.
12/15/18	Revision; Guardant360 test and OncoBEAM test added to the circulating tumor DNA for management of NSCLC position statement; investigational statement for microarray-based gene expression profile testing for multiple myeloma added; molecular analysis for targeted therapy of NSCLC position statements updated; coding, and references updated.
01/01/19	Annual CPT/HCPCS coding update. Added codes 81345, 81596; deleted code 0001M.
02/15/18	Revision; Fecal calprotectin testing position revised; coding and references updated.
05/15/19	Revision; Serum Biomarker Human Epididymis Protein 4 position statement added; references updated.
06/15/19	Revision; Xpresys test deleted (test no longer on the market).
07/01/19	Quarterly CPT/HCPCS update; Added codes 0089U-0092U. Revision; Gene expression profiling for cutaneous melanoma & molecular testing in the management of pulmonary nodules position statements added; OVA1 status maintained; coding and references updated.
08/15/19	Revision; Afirma test name updated.
01/01/20	Review; Analysis for targeted therapy of NSCLC & circulating tumor DNA for management of NSCLC statements updated; coding and references updated. Annual CPT/HCPCS coding update. Added codes 80145, 80230, 80280, 81552; deleted code 0081U.
04/01/20	Quarterly CPT/HCPCS update. Added code 0166U.

05/15/20	Coding and references updated.
07/01/20	Gene expression profiling for cutaneous melanoma reviewed and position statements maintained; references updated. Quarterly CPT/HCPCS update. Added codes 0174U & 0179U.
09/15/20	Revision; References updated.
09/18/20	Revision; Liquid biopsy test names updated.
10/01/20	Quarterly CPT/HCPCS update. Added codes 0016M, 0204U-0208U, and 0211U.
11/15/20	Revision; coding and references updated.
01/01/21	Annual CPT/HCPCS update. Codes 81191-81194,81529,81546,81554 added; codes 81545, 0111T deleted.
02/15/21	Review; Circulating tumor DNA management of NSCLC, molecular analysis for targeted therapy for NSCLC, measurement of serum antibodies to selected biologic agents, and pharmacogenomics markers for members treated with thiopurines position statements updated; coding and references updated.
04/01/21	Quarterly CPT/HCPCS update. Codes 0242U, 0244U, 0245U added.
04/16/21	Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy) statement added.
05/15/21	Revision; Homocysteine position statement deleted; investigational test list, coding and references updated.
06/15/21	Reimbursement section updated.
07/01/21	Quarterly CPT/HCPCS update. Codes 0249U and 0250U added.
08/15/21	Review; DecisionDx-Melanoma position statement maintained, references updated.
09/03/21	Revision: Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy) section updated.
10/15/21	Review; OVA1 position statement maintained, references updated.
11/15/21	Revision; Fecal Calprotectin position statement removed; coding and references updated.
01/01/22	Annual CPT/HCPCS coding update. Codes 0287U, 0288U added; 0090U revised; 0208U deleted.
02/15/22	Revision: Liquid biopsy for management of NSCLC position statements moved to the molecular analysis for targeted therapy or immunotherapy of NSCLC section; statements for KRAS testing for treatment with sotorasib added; coding and references updated.
04/01/22	Quarterly CPT/HCPCS update. Code 0314U added.
04/29/22	Codes 81445-81455 removed.
06/15/22	Expanded test panel list updated.
07/01/22	Review: Gene expression profiling for cutaneous melanoma position statements maintained; references updated. Quarterly CPT/HCPCS update: code 0016M revised.
08/15/22	Review: OVA1 position statement maintained; references updated.
09/15/22	Review: Comprehensive genomic profiling statement removed; investigational test list, coding section, and references updated.
10/01/22	Revision: Tumor-informed circulating tumor DNA testing for cancer management investigational statement added; references updated. Quarterly CPT/HCPCS update. Codes 0337U, 0338U, 0340U added; codes 0013U, 0014U, 0056U deleted.



11/15/22	Revision: Gene expression profiling for colorectal cancer statement added; coding and references updated.
01/01/23	Annual CPT/HCPCS coding update. Codes 84433 and 0363U added.
06/15/23	Revision: Note added to the position statement section. References and coding updated.
07/15/23	Revision: Gene expression profiling for cutaneous melanoma position statements maintained; investigational test list, coding, and references updated.
08/15/23	Revision: Multicancer early detection testing investigational position statement added; references updated.
10/01/23	Revision: Position statements, coding, and references updated. Quarterly CPT/HCPCS coding update: Code 0412U added.
11/15/23	Revision: Multimarker serum testing related to ovarian cancer statement updated; investigational test list, coding, and references updated.
01/01/24	Position statements maintained. Annual CPT/HCPCS coding update. Codes 81517, 0420U added. Program exception and references updated.
03/15/24	Coding and references updated.
04/01/24	Quarterly CPT/HCPCS coding update: Code 0445U added.
04/15/24	Investigational test list, coding, and references updated.
07/01/24	Quarterly CPT/HCPCS coding update. Code 0204U deleted.